Novozymes As B Stock Price Prediction
| NVZMF Stock | USD 58.55 0.93 1.56% |
Oversold Vs Overbought
34
Oversold | Overbought |
Using Novozymes A/S hype-based prediction, you can estimate the value of Novozymes AS B from the perspective of Novozymes A/S response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Novozymes A/S to buy its pink sheet at a price that has no basis in reality. In that case, they are not buying Novozymes because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell pink sheets at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Novozymes A/S after-hype prediction price | USD 59.48 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as pink sheet price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Novozymes |
Novozymes A/S After-Hype Price Prediction Density Analysis
As far as predicting the price of Novozymes A/S at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Novozymes A/S or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Pink Sheet prices, such as prices of Novozymes A/S, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Novozymes A/S Estimiated After-Hype Price Volatility
In the context of predicting Novozymes A/S's pink sheet value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Novozymes A/S's historical news coverage. Novozymes A/S's after-hype downside and upside margins for the prediction period are 56.72 and 62.24, respectively. We have considered Novozymes A/S's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Novozymes A/S is very steady at this time. Analysis and calculation of next after-hype price of Novozymes AS B is based on 3 months time horizon.
Novozymes A/S Pink Sheet Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Novozymes A/S is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Novozymes A/S backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Pink Sheet price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Novozymes A/S, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.21 | 2.76 | 0.00 | 0.00 | 0 Events / Month | 0 Events / Month | Uncertain |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
58.55 | 59.48 | 0.00 |
|
Novozymes A/S Hype Timeline
Novozymes AS B is now traded for 58.55. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Novozymes is expected not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is expected to be very small, whereas the daily expected return is now at -0.21%. %. The volatility of related hype on Novozymes A/S is about 276000.0%, with the expected price after the next announcement by competition of 58.55. About 42.0% of the company shares are owned by institutional investors. The company last dividend was issued on the 3rd of March 2023. Novozymes AS B had 5:1 split on the 28th of November 2011. Assuming the 90 days horizon the next expected press release will be uncertain. Check out Novozymes A/S Basic Forecasting Models to cross-verify your projections.Novozymes A/S Related Hype Analysis
Having access to credible news sources related to Novozymes A/S's direct competition is more important than ever and may enhance your ability to predict Novozymes A/S's future price movements. Getting to know how Novozymes A/S's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Novozymes A/S may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| FGPHF | First Graphene | 0.00 | 0 per month | 0.00 | (0.03) | 12.50 | (16.00) | 41.74 | |
| 444859BR2 | HUMANA INC | 0.00 | 0 per month | 0.00 | (0.07) | 5.93 | (4.56) | 16.62 | |
| AQUI | Aquagold International | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| BRRAY | Barloworld Ltd ADR | 0.00 | 0 per month | 0.00 | (0.03) | 0.00 | (2.98) | 34.02 | |
| MSTSX | Morningstar Unconstrained Allocation | 0.00 | 0 per month | 0.50 | (0.13) | 1.21 | (1.02) | 2.80 | |
| ABHYX | High Yield Municipal Fund | (0.01) | 1 per month | 0.26 | (0.41) | 0.34 | (0.33) | 1.91 | |
| LBHIX | Thrivent High Yield | 0.00 | 0 per month | 0.00 | (0.60) | 0.24 | (0.24) | 0.96 | |
| SCAXF | Sparta Capital | 0.00 | 0 per month | 0.00 | (0.17) | 0.00 | 0.00 | 23.47 | |
| VIASP | Via Renewables | 0.00 | 0 per month | 1.05 | (0.02) | 2.28 | (1.15) | 7.18 | |
| RRTLX | T Rowe Price | 0.00 | 0 per month | 0.24 | (0.34) | 0.56 | (0.56) | 1.37 |
Novozymes A/S Additional Predictive Modules
Most predictive techniques to examine Novozymes price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Novozymes using various technical indicators. When you analyze Novozymes charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Novozymes A/S Predictive Indicators
The successful prediction of Novozymes A/S stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Novozymes AS B, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Novozymes A/S based on analysis of Novozymes A/S hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Novozymes A/S's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Novozymes A/S's related companies.
Story Coverage note for Novozymes A/S
The number of cover stories for Novozymes A/S depends on current market conditions and Novozymes A/S's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Novozymes A/S is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Novozymes A/S's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
Novozymes A/S Short Properties
Novozymes A/S's future price predictability will typically decrease when Novozymes A/S's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Novozymes AS B often depends not only on the future outlook of the potential Novozymes A/S's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Novozymes A/S's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 276.6 M |
Complementary Tools for Novozymes Pink Sheet analysis
When running Novozymes A/S's price analysis, check to measure Novozymes A/S's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novozymes A/S is operating at the current time. Most of Novozymes A/S's value examination focuses on studying past and present price action to predict the probability of Novozymes A/S's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novozymes A/S's price. Additionally, you may evaluate how the addition of Novozymes A/S to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |